Leerink Swann Weighs in on Sanofi’s Q3 2017 Earnings (SNY)
Sanofi (NYSE:SNY) – Research analysts at Leerink Swann increased their Q3 2017 EPS estimates for shares of Sanofi in a research note issued on Monday. Leerink Swann analyst S. Fernandez now expects that the company will post earnings per share of $0.95 for the quarter, up from their previous forecast of $0.90. Leerink Swann also issued estimates for Sanofi’s FY2018 earnings at $3.32 EPS, FY2019 earnings at $3.65 EPS, FY2020 earnings at $3.89 EPS and FY2021 earnings at $4.08 EPS.
SNY has been the subject of a number of other reports. Cowen and Company reaffirmed a “market perform” rating and set a $52.00 price objective (up from $46.00) on shares of Sanofi in a report on Tuesday, August 1st. BidaskClub raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Saturday, August 5th. Argus reaffirmed a “buy” rating and set a $55.00 price objective on shares of Sanofi in a report on Friday, September 1st. Zacks Investment Research downgraded shares of Sanofi from a “hold” rating to a “strong sell” rating in a report on Friday, October 6th. Finally, J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Sanofi in a report on Friday, September 15th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $53.50.
Shares of Sanofi (NYSE:SNY) opened at 49.01 on Wednesday. The company has a market cap of $123.09 billion, a P/E ratio of 11.38 and a beta of 0.87. The company’s 50 day moving average is $49.53 and its 200-day moving average is $48.41. Sanofi has a 12 month low of $36.81 and a 12 month high of $50.65.
Sanofi (NYSE:SNY) last announced its quarterly earnings data on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.74. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The business had revenue of $8.66 billion during the quarter, compared to the consensus estimate of $8.71 billion. The company’s quarterly revenue was down 2.3% on a year-over-year basis.
In other news, major shareholder Sanofi bought 60,595 shares of the company’s stock in a transaction that occurred on Wednesday, August 23rd. The stock was acquired at an average price of $478.98 per share, for a total transaction of $29,023,793.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 1.00% of the company’s stock.
Several institutional investors have recently made changes to their positions in the stock. Pennsylvania Trust Co increased its position in shares of Sanofi by 0.4% during the 2nd quarter. Pennsylvania Trust Co now owns 8,314 shares of the company’s stock worth $402,000 after purchasing an additional 37 shares in the last quarter. Moors & Cabot Inc. increased its position in shares of Sanofi by 0.7% during the 2nd quarter. Moors & Cabot Inc. now owns 6,494 shares of the company’s stock worth $311,000 after purchasing an additional 43 shares in the last quarter. Rehmann Capital Advisory Group increased its position in shares of Sanofi by 0.7% during the 2nd quarter. Rehmann Capital Advisory Group now owns 7,235 shares of the company’s stock worth $347,000 after purchasing an additional 47 shares in the last quarter. Strategic Global Advisors LLC increased its position in shares of Sanofi by 0.6% during the 2nd quarter. Strategic Global Advisors LLC now owns 8,632 shares of the company’s stock worth $414,000 after purchasing an additional 54 shares in the last quarter. Finally, First City Capital Management Inc. increased its position in shares of Sanofi by 0.3% during the 2nd quarter. First City Capital Management Inc. now owns 38,389 shares of the company’s stock worth $1,839,000 after purchasing an additional 100 shares in the last quarter. Institutional investors and hedge funds own 9.35% of the company’s stock.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.